Citadel Advisors
OVID icon

Citadel Advisors’s Ovid Therapeutics OVID Stock Holding History

Citadel Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.9K Sell
19,300
-1,200
-6% -$3.1K ﹤0.01% 13097
2026
Q1 		$45.5K Buy
20,500
+3,800
+23% +$6.79K ﹤0.01% 12436
2025
Q4 		$27.2K Sell
16,700
-45,800
-73% -$70.5K ﹤0.01% 12258
2025
Q3 		$81.3K Buy
+62,500
New +$54.2K ﹤0.01% 11965
2025
Q2 		– Sell
-100
Closed -$31 – 14374
2025
Q1 		$31 Sell
100
-100
-50% -$61 ﹤0.01% 14350
2024
Q4 		$187 Sell
200
-300
-60% -$336 ﹤0.01% 14370
2024
Q3 		$590 Buy
500
+300
+150% +$313 ﹤0.01% 13990
2024
Q2 		$154 Sell
200
-100
-33% -$278 ﹤0.01% 14085
2024
Q1 		$915 Buy
+300
New +$1K ﹤0.01% 14224
2023
Q3 		– Sell
-200
Closed -$656 – 14869
2023
Q2 		$656 Hold
200
– – ﹤0.01% 14069
2023
Q1 		$516 Buy
+200
New +$474 ﹤0.01% 14478
2021
Q4 		– Sell
-33,800
Closed -$114K – 14477
2021
Q3 		$114K Buy
33,800
+3,500
+12% +$12.8K ﹤0.01% 12705
2021
Q2 		$118K Sell
30,300
-95,300
-76% -$376K ﹤0.01% 12763
2021
Q1 		$505K Buy
125,600
+2,500
+2% +$8.3K ﹤0.01% 9660
2020
Q4 		$284K Buy
123,100
+80,600
+190% +$376K ﹤0.01% 9165
2020
Q3 		$244K Buy
42,500
+13,000
+44% +$87K ﹤0.01% 8484
2020
Q2 		$217K Buy
+29,500
New +$138K ﹤0.01% 8409

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors's OVID Position: Q2 2026 in Review

Citadel Advisors sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 367,902 shares — an estimated $949K sold.

Citadel Advisors first reported a position in OVID in Q2 2017 and held it in 21 quarters. The position peaked at $1.3M in Q4 2025. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Citadel Advisors reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 367,902 Ovid Therapeutics shares in Q2 2026, an estimated $949K.
  • Citadel Advisors first reported a position in Ovid Therapeutics in Q2 2017 and held it in 21 quarters.
  • Citadel Advisors's Ovid Therapeutics position peaked at $1.3M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.